Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.
Baur R
,
Gertsch J
,
Sigel E
.
???displayArticle.abstract???
Rimonabant (SR141716) and the structurally related AM251 are widely used in pharmacological experiments as selective cannabinoid receptor CB(1) antagonists / inverse agonists. Concentrations of 0.5-10 µM are usually applied in in vitro experiments. We intended to show that these drugs did not act at GABA(A) receptors but found a significant positive allosteric modulation instead. Recombinant GABA(A) receptors were expressed in Xenopus oocytes. Receptors were exposed to AM251 or rimonabant in the absence and presence of GABA. Standard electrophysiological techniques were used to monitor the elicited ionic currents. AM251 dose-dependently potentiated responses to 0.5 µM GABA at the recombinant α(1) β(2) γ(2) GABA(A) receptor with an EC(50) below 1 µM and a maximal potentiation of about eightfold. The Hill coefficient indicated that more than one binding site for AM251 was located in this receptor. Rimonabant had a lower affinity, but a fourfold higher efficacy. AM251 potentiated also currents mediated by α(1) β(2) , α(x) β(2) γ(2) (x = 2,3,5,6), α(1) β(3) γ(2) and α(4) β(2) δ GABA(A) receptors, but not those mediated by α(1) β(1) γ(2) . Interestingly, the CB(1) receptor antagonists LY320135 and O-2050 did not significantly affect α(1) β(2) γ(2) GABA(A) receptor-mediated currents at concentrations of 1 µM. This study identified rimonabant and AM251 as positive allosteric modulators of GABA(A) receptors. Thus, potential GABAergic effects of commonly used concentrations of these compounds should be considered in in vitro experiments, especially at extrasynaptic sites where GABA concentrations are low. This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue-7.
Alexander,
Guide to Receptors and Channels (GRAC), 5th edition.
2011, Pubmed
Alexander,
Guide to Receptors and Channels (GRAC), 5th edition.
2011,
Pubmed
Barna,
Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: compound-specific and area-specific distribution within the brain.
2009,
Pubmed
Baur,
Replacement of histidine in position 105 in the α₅ subunit by cysteine stimulates zolpidem sensitivity of α₅β₂γ₂ GABA(A) receptors.
2007,
Pubmed
,
Xenbase
Boileau,
The relative amount of cRNA coding for gamma2 subunits affects stimulation by benzodiazepines in GABA(A) receptors expressed in Xenopus oocytes.
2002,
Pubmed
,
Xenbase
Di Marzo,
CB(1) receptor antagonism: biological basis for metabolic effects.
2008,
Pubmed
Felder,
LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.
1998,
Pubmed
Fernandez,
Rimonabant Sanofi-Synthélabo.
2004,
Pubmed
Gardner,
Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'.
2006,
Pubmed
Gatley,
Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors.
1997,
Pubmed
Gibson,
TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons.
2008,
Pubmed
Hashimotodani,
Endocannabinoids and synaptic function in the CNS.
2007,
Pubmed
Karsak,
Attenuation of allergic contact dermatitis through the endocannabinoid system.
2007,
Pubmed
Katona,
Endocannabinoid signaling as a synaptic circuit breaker in neurological disease.
2008,
Pubmed
Kim,
Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses.
2010,
Pubmed
Kunos,
Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?
2007,
Pubmed
Kunos,
Endocannabinoids and the control of energy homeostasis.
2008,
Pubmed
Kunos,
Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?
2009,
Pubmed
Leonti,
Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin.
2010,
Pubmed
Lutz,
Endocannabinoid signals in the control of emotion.
2009,
Pubmed
Macdonald,
GABAA receptor channels.
1994,
Pubmed
Mendiguren,
Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices.
2009,
Pubmed
Menzies,
Direct and indirect effects of cannabinoids on in vitro GABA release in the rat arcuate nucleus.
2010,
Pubmed
Minier,
Positioning of the alpha-subunit isoforms confers a functional signature to gamma-aminobutyric acid type A receptors.
2004,
Pubmed
,
Xenbase
Pertwee,
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.
2010,
Pubmed
Petrosino,
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
2010,
Pubmed
Piomelli,
The endocannabinoid system: a drug discovery perspective.
2005,
Pubmed
Rabow,
From ion currents to genomic analysis: recent advances in GABAA receptor research.
1995,
Pubmed
Ross,
The enigmatic pharmacology of GPR55.
2009,
Pubmed
Seo,
Genetic reduction of GABA(A) receptor gamma2 subunit expression potentiates the immobilizing action of isoflurane.
2010,
Pubmed
Sieghart,
Subunit composition, distribution and function of GABA(A) receptor subtypes.
2002,
Pubmed
Sigel,
Properties of single sodium channels translated by Xenopus oocytes after injection with messenger ribonucleic acid.
1987,
Pubmed
,
Xenbase
Sigel,
The Xenopus oocyte: system for the study of functional expression and modulation of proteins.
2005,
Pubmed
,
Xenbase
Solinas,
The endocannabinoid system in brain reward processes.
2008,
Pubmed
